127 related articles for article (PubMed ID: 20961062)
1. Indazolylpyrazolopyrimidine as highly potent B-Raf inhibitors with in vivo activity.
Wang X; Berger DM; Salaski EJ; Torres N; Dutia M; Hanna C; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E; Lucas J
J Med Chem; 2010 Nov; 53(21):7874-8. PubMed ID: 20961062
[TBL] [Abstract][Full Text] [Related]
2. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.
Ren L; Laird ER; Buckmelter AJ; Dinkel V; Gloor SL; Grina J; Newhouse B; Rasor K; Hastings G; Gradl SN; Rudolph J
Bioorg Med Chem Lett; 2012 Jan; 22(2):1165-8. PubMed ID: 22196124
[TBL] [Abstract][Full Text] [Related]
3. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
[TBL] [Abstract][Full Text] [Related]
4. Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.
Mathieu S; Gradl SN; Ren L; Wen Z; Aliagas I; Gunzner-Toste J; Lee W; Pulk R; Zhao G; Alicke B; Boggs JW; Buckmelter AJ; Choo EF; Dinkel V; Gloor SL; Gould SE; Hansen JD; Hastings G; Hatzivassiliou G; Laird ER; Moreno D; Ran Y; Voegtli WC; Wenglowsky S; Grina J; Rudolph J
J Med Chem; 2012 Mar; 55(6):2869-81. PubMed ID: 22335519
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.
Medina JR; Becker CJ; Blackledge CW; Duquenne C; Feng Y; Grant SW; Heerding D; Li WH; Miller WH; Romeril SP; Scherzer D; Shu A; Bobko MA; Chadderton AR; Dumble M; Gardiner CM; Gilbert S; Liu Q; Rabindran SK; Sudakin V; Xiang H; Brady PG; Campobasso N; Ward P; Axten JM
J Med Chem; 2011 Mar; 54(6):1871-95. PubMed ID: 21341675
[TBL] [Abstract][Full Text] [Related]
6. Hit to lead optimization of pyrazolo[1,5-a]pyrimidines as B-Raf kinase inhibitors.
Gopalsamy A; Ciszewski G; Shi M; Berger D; Hu Y; Lee F; Feldberg L; Frommer E; Kim S; Collins K; Wojciechowicz D; Mallon R
Bioorg Med Chem Lett; 2009 Dec; 19(24):6890-2. PubMed ID: 19884006
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.
Ishikawa T; Seto M; Banno H; Kawakita Y; Oorui M; Taniguchi T; Ohta Y; Tamura T; Nakayama A; Miki H; Kamiguchi H; Tanaka T; Habuka N; Sogabe S; Yano J; Aertgeerts K; Kamiyama K
J Med Chem; 2011 Dec; 54(23):8030-50. PubMed ID: 22003817
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and anti-tumor activities of some new pyridines and pyrazolo[1,5-a]pyrimidines.
Ahmed OM; Mohamed MA; Ahmed RR; Ahmed SA
Eur J Med Chem; 2009 Sep; 44(9):3519-23. PubMed ID: 19398146
[TBL] [Abstract][Full Text] [Related]
9. Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells.
Carraro F; Pucci A; Naldini A; Schenone S; Bruno O; Ranise A; Bondavalli F; Brullo C; Fossa P; Menozzi G; Mosti L; Manetti F; Botta M
J Med Chem; 2004 Mar; 47(7):1595-8. PubMed ID: 15027847
[TBL] [Abstract][Full Text] [Related]
10. Novel pyrazolopyrimidines as highly potent B-Raf inhibitors.
Di Grandi MJ; Berger DM; Hopper DW; Zhang C; Dutia M; Dunnick AL; Torres N; Levin JI; Diamantidis G; Zapf CW; Bloom JD; Hu Y; Powell D; Wojciechowicz D; Collins K; Frommer E
Bioorg Med Chem Lett; 2009 Dec; 19(24):6957-61. PubMed ID: 19875283
[TBL] [Abstract][Full Text] [Related]
11. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.
Berger DM; Torres N; Dutia M; Powell D; Ciszewski G; Gopalsamy A; Levin JI; Kim KH; Xu W; Wilhelm J; Hu Y; Collins K; Feldberg L; Kim S; Frommer E; Wojciechowicz D; Mallon R
Bioorg Med Chem Lett; 2009 Dec; 19(23):6519-23. PubMed ID: 19864136
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.
Sutherlin DP; Bao L; Berry M; Castanedo G; Chuckowree I; Dotson J; Folks A; Friedman L; Goldsmith R; Gunzner J; Heffron T; Lesnick J; Lewis C; Mathieu S; Murray J; Nonomiya J; Pang J; Pegg N; Prior WW; Rouge L; Salphati L; Sampath D; Tian Q; Tsui V; Wan NC; Wang S; Wei B; Wiesmann C; Wu P; Zhu BY; Olivero A
J Med Chem; 2011 Nov; 54(21):7579-87. PubMed ID: 21981714
[TBL] [Abstract][Full Text] [Related]
13. Preparation of 3-substituted-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines as RET kinase inhibitors.
Dinér P; Alao JP; Söderlund J; Sunnerhagen P; Grøtli M
J Med Chem; 2012 May; 55(10):4872-6. PubMed ID: 22559926
[TBL] [Abstract][Full Text] [Related]
14. Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines.
Manetti F; Brullo C; Magnani M; Mosci F; Chelli B; Crespan E; Schenone S; Naldini A; Bruno O; Trincavelli ML; Maga G; Carraro F; Martini C; Bondavalli F; Botta M
J Med Chem; 2008 Mar; 51(5):1252-9. PubMed ID: 18257513
[TBL] [Abstract][Full Text] [Related]
15. Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.
Gould AE; Adams R; Adhikari S; Aertgeerts K; Afroze R; Blackburn C; Calderwood EF; Chau R; Chouitar J; Duffey MO; England DB; Farrer C; Forsyth N; Garcia K; Gaulin J; Greenspan PD; Guo R; Harrison SJ; Huang SC; Iartchouk N; Janowick D; Kim MS; Kulkarni B; Langston SP; Liu JX; Ma LT; Menon S; Mizutani H; Paske E; Renou CC; Rezaei M; Rowland RS; Sintchak MD; Smith MD; Stroud SG; Tregay M; Tian Y; Veiby OP; Vos TJ; Vyskocil S; Williams J; Xu T; Yang JJ; Yano J; Zeng H; Zhang DM; Zhang Q; Galvin KM
J Med Chem; 2011 Mar; 54(6):1836-46. PubMed ID: 21341678
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP
J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345
[TBL] [Abstract][Full Text] [Related]
17. Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex.
Echalier A; Bettayeb K; Ferandin Y; Lozach O; Clément M; Valette A; Liger F; Marquet B; Morris JC; Endicott JA; Joseph B; Meijer L
J Med Chem; 2008 Feb; 51(4):737-51. PubMed ID: 18232649
[TBL] [Abstract][Full Text] [Related]
18. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.
Zask A; Verheijen JC; Curran K; Kaplan J; Richard DJ; Nowak P; Malwitz DJ; Brooijmans N; Bard J; Svenson K; Lucas J; Toral-Barza L; Zhang WG; Hollander I; Gibbons JJ; Abraham RT; Ayral-Kaloustian S; Mansour TS; Yu K
J Med Chem; 2009 Aug; 52(16):5013-6. PubMed ID: 19645448
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and anti-tumor activities of novel pyrazolo[1,5-a]pyrimidines.
Li J; Zhao YF; Zhao XL; Yuan XY; Gong P
Arch Pharm (Weinheim); 2006 Nov; 339(11):593-7. PubMed ID: 17036367
[TBL] [Abstract][Full Text] [Related]
20. Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer.
Antonelli A; Bocci G; La Motta C; Ferrari SM; Fallahi P; Fioravanti A; Sartini S; Minuto M; Piaggi S; Corti A; Alì G; Berti P; Fontanini G; Danesi R; Da Settimo F; Miccoli P
J Clin Endocrinol Metab; 2011 Feb; 96(2):E288-96. PubMed ID: 21147882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
